Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders in Canada. Its product candidates include Azetukalner, a selective Kv7 potassium channel opener in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a Nav1.2/1.6 sodium channel inhibitor that is in Phase 1 clinical trials for the treatment of certain types of epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.

Period	Debt/Equity
2015-12-31	0.05
2016-12-31	0.06
2017-12-31	0.28
2018-12-31	0.19
2019-12-31	0.48
2020-12-31	0.10
2021-12-31	0.04
2022-12-31	0.05
2023-12-31	0.04
2024-12-31	0.06

	A	B	C	D
1	Symbol	Price	Change	Volume
2	XENE	$57.17	-0.82%	0.41M
3
4
5

Xenon Pharmaceuticals Inc. (XENE) Debt to Equity Ratio

Debt to Equity Ratio Data

Get Xenon Pharmaceuticals Inc. Data in Excel

More XENE Financial Data